About Crown Bioscience
Crown Bioscience is a global contract research organization (CRO) providing discovery, preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. Founded in 2006, Crown Bioscience has eleven facilities across the US, Europe, and Asia.
Known for their high quality and expansive in vivo, in vitro and ex vivo preclinical models, they partner with their clients to quantify the efficacy and pharmacological profile of their drug candidate before they move into the clinic.
The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Additionally, services available in the areas of high content imaging and a 3D Ex Vivo Patient Tissue Platform, provide greater insights into complex disease pathophysiology. A complementary range of biomarker analysis and applied genomics services are also available to optimize therapeutic benefit.
In partnership with their customers, Crown Bioscience aims to realize a world where every patient gets the right treatment, at the right time.